1 Introduction Thyroid cancer is the most prevalent endocrine malignancy, with its global incidence having risen substantially over the past four decades [1]. While the vast majority of differentiated thyroid cancers—particularly papillary thyroid carcinoma (PTC)—carry an excellent prognosis following standard treatment with surgery, radioactive iodine, and thyroid-stimulating hormone suppression, a small subset of patients develops highly aggressive, undifferentiated disease [2].
